BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 3:52:00 PM | Browse: 1364 | Download: 1941
Publication Name World Journal of Gastroenterology
Manuscript ID 5525
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma
Manuscript Source Invited Manuscript
All Author List Wei-Ping Liu, Wen Zheng, Yu-Qin Song, Ling-Yan Ping, Gui-Qiang Wang and Jun Zhu
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81241073
Peking University Cancer Hospital Foundation for Scientific Research 2013-Autonomous-9
Corresponding Author Jun Zhu, MD, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. zhu-jun@bjcancer.org
Key Words Hepatitis B surface antigen; Seroconversion; Non-Hodgkin’s lymphoma; Rituximab; Entecavir
Core Tip We describe the case of a 68-year-old hepatitis B surface antigen (HBsAg)-positive male patient who received rituximab-based immunochemotherapy for follicular lymphoma, and experienced hepatitis B virus (HBV) reactivation following cessation of lamivudine prophylaxis. Subsequent entecavir treatment produced rapid, sustained viral suppression and HBsAg seroconversion. Lamivudine prevents HBV reactivation but resistance rates may be as high as 17% in lymphoma patients. Available data suggest that entecavir is effective and safe for the treatment of HBV reactivation in lymphoma patients. Prophylactic antiviral therapy is recommended for patients with active or occult HBV infection following chemotherapy or immunochemotherapy. Potent antiviral drugs with a high genetic barrier to resistance should be considered in these cases.
Publish Date 2014-05-07 10:10
Citation Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma. World J Gastroenterol 2014; 20(17): 5165-5170
URL http://www.wjgnet.com/1007-9327/full/v20/i17/5165.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i17.5165
Full Article (PDF) WJG-20-5165.pdf
Full Article (Word) WJG-20-5165.doc